A New Epigenetic Key to Unlocking Chemoresistance in Cancer
A study published in *Cell Death & Differentiation* reveals a critical epigenetic mechanism driving chemoresistance in breast cancer. Researchers identified that the USP7-PRMT6 axis coordinates two key processes: the deposition of the H3R2me2a histone mark and the methylation of the DNA repair protein RNF168. This dual action simultaneously enhances DNA repair capacity and blocks a form of cell death called ferroptosis, allowing cancer cells to survive chemotherapy. Targeting this specific axis presents a novel therapeutic strategy to overcome treatment resistance.
Why it might matter to you: This research on epigenetic regulation of cell survival pathways has significant translational potential for neuropsychiatry. The mechanistic insights into blocking ferroptosis—a process increasingly implicated in neurodegenerative and mood disorders—could inform the development of novel neuroprotective agents. For a psychiatrist focused on the biological underpinnings of mental illness, understanding how epigenetic modifiers influence cellular resilience may open new avenues for conceptualizing treatment resistance in conditions like major depression.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
